Cipla gets EIR from USFDA for Indore plant

23 Sep 2022 Evaluate

Cipla has received the Establishment Inspection Report (EIR) for its Indore plant, indicating closure of the inspection. The United States Food and Drug Administration (USFDA) had conducted product-specific pre-approval inspection (PAI) at the Indore plant on June 27 and July 1.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1321.60 6.75 (0.51%)
27-Jan-2026 13:13 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1630.00
Dr. Reddys Lab 1238.90
Cipla 1321.60
Zydus Lifesciences 889.25
Lupin 2135.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×